Use of Second-Generation Oral SERDs in ER+/HER2- mBC

Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.

Related Videos
William M. Sikov, MD
Lisa A. Carey MD, ScM, FASCO
Susan Domchek, MD, FASCO
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Jean Wright, MD
Steven Cai, MD, FACS
Hyman B. Muss, MD
Expert on breast cancer
Priyanka Sharma, MD
Rima Patel, MD
Related Content

FDA Lifts Partial Hold on VELA Trial Evaluating BLU-222 in Advanced Solid Tumors

March 29th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Trastuzumab Deruxtecan Garners Approval in Japan for HER2-Low Metastatic Breast Cancer

March 27th 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

March 23rd 2023

FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection

March 21st 2023

FDA Lifts Partial Hold on VELA Trial Evaluating BLU-222 in Advanced Solid Tumors

March 29th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Trastuzumab Deruxtecan Garners Approval in Japan for HER2-Low Metastatic Breast Cancer

March 27th 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

March 23rd 2023

FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection

March 21st 2023

FDA Lifts Partial Hold on VELA Trial Evaluating BLU-222 in Advanced Solid Tumors

March 29th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Trastuzumab Deruxtecan Garners Approval in Japan for HER2-Low Metastatic Breast Cancer

March 27th 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

March 23rd 2023

FDA Approval Sought for Lumisight Optical Imaging Agent to Assist in Intraoperative Breast Cancer Detection

March 21st 2023